首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1738904

2026 年至 2032 年胰島素幫浦市場（按幫浦類型、應用、最終用戶和地區分類）

Insulin Pumps Market By Type of Pump (Traditional Insulin Pumps, Patch Pumps, Tubeless Pumps), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), End User (Hospitals, Homecare, Labs), & Region for 2026-2032

出版日期: 2025年05月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

胰島素幫浦市場估值，2026-2032

生活方式的改變和人口老化正在增加糖尿病的盛行率，尤其是第1型和第2型糖尿病。胰島素幫浦設計和功能的技術進步，例如與持續血糖監測系統的整合和智慧功能，提升了使用者體驗和血糖值管理的有效性。胰島素幫浦的需求將在2024年超過255.6億美元，並在2032年達到695.4億美元。

此外，政府的支持政策和優惠的報銷政策使得胰島素幫浦的使用更加便捷，同時，醫護人員和病患對胰島素治療益處的認知和教育程度的不斷提高也推動了其普及率。這些因素推動了各行各業胰島素幫浦使用量的上升，預計2026年至2032年期間的複合年成長率約為14.70%。

胰島素幫浦市場定義/概述

胰島素幫浦是一種小型攜帶式醫療設備，旨在為糖尿病患者持續輸送胰島素，從而實現精準且可調節的胰島素劑量，從而有效管理血糖值。這類設備主要供第1型糖尿病患者使用，但第二型糖尿病患者也越來越多開始使用。胰島素幫浦具有多種應用，包括基礎胰島素和Bolus胰島素輸送、與持續血糖監測系統整合，以及可程式設計功能，可提高使用者的便利性和對糖尿病管理的控制力。展望未來，隨著閉合迴路系統（人工胰臟技術）的發展等技術進步、糖尿病管理意識的增強以及全球糖尿病盛行率的上升，胰島素幫浦市場預計將顯著成長。

糖尿病盛行率上升會推動胰島素幫浦市場的發展嗎？

糖尿病盛行率的上升極大地推動了胰島素幫浦市場的發展。隨著全球人口的成長和老化，糖尿病，尤其是第 2 型糖尿病的盛行率正在上升。根據國際糖尿病聯盟 (IDF) 的數據，2021 年全球約有 5.37 億成年人患有糖尿病，預計到 2045 年將達到 7.83 億。在美國，疾病管制與預防中心 (CDC) 報告稱，2022 年將有約 3,730 萬人患有糖尿病，約佔總人口的 11.3%。糖尿病患者數量的增加與對有效管理解決方案（包括胰島素幫浦）的需求不斷成長直接相關。

隨著人們日益意識到胰島素幫浦的益處，包括改善血糖控制和提高胰島素給藥的靈活性，對先進糖尿病管理工具的需求也日益凸顯。隨著醫療保健提供者倡導創新治療方法以幫助患者有效管理病情，胰島素幫浦正成為糖尿病護理的重要組成部分。美國疾病管制與預防中心 (CDC) 也強調，有效管理糖尿病可以減少併發症，提高生活品質，並降低醫療成本。

高昂的開發成本是否會阻礙胰島素幫浦市場的成長？

高昂的開發成本確實是阻礙胰島素幫浦市場成長的關鍵因素。先進的胰島素幫浦技術需要在研發、合規性和臨床試驗方面投入大量資金，以確保安全性和有效性。這些成本可能會阻礙小公司進入市場並限制競爭，導致創新解決方案減少和技術進步放緩。此外，胰島素幫浦的高價格通常意味著更高的零售價格，這會限制患者的使用，尤其是在保險覆蓋範圍有限且自付費用較高的地區。

此外，高昂的開發成本所帶來的財務負擔可能會影響製造商的定價策略。公司可能被迫將這些成本轉嫁給消費者，導致胰島素幫浦價格上漲，並限制其在潛在用戶中的普及。這對第二型糖尿病患者尤其有害，因為患者可能不願意投資那些無法帶來即時健康益處的昂貴設備。

The rising prevalence of diabetes, particularly Type 1 and Type 2, driven by lifestyle changes and an aging population. Technological advancements in insulin pump design and functionality, such as integration with continuous glucose monitoring systems and smart features, enhance user experience and effectiveness in managing blood glucose levels. The need for insulin pumps is surpassing USD 25.56 Billion in 2024 and reaching USD 69.54 Billion by 2032.

Additionally, supportive government initiatives and favorable reimbursement policies are making insulin pumps more accessible, while increased awareness and education among healthcare professionals and patients about the benefits of insulin therapy further boost adoption rates. These factors contribute to the increasing use of insulin pumps in a variety of industries is expected to grow at a CAGR of 14.70% about from 2026 to 2032.

Insulin Pumps Market: Definition/ Overview

Insulin pumps are small, portable medical devices designed to deliver continuous insulin to individuals with diabetes, allowing for precise and adjustable insulin administration to manage blood glucose levels effectively. These devices are primarily used by people with Type 1 Diabetes, but they are increasingly being adopted by those with Type 2 Diabetes as well. Insulin pumps provide various applications, including basal and bolus insulin delivery, integration with continuous glucose monitoring systems, and programmable features that enhance user convenience and control over their diabetes management. Looking to the future, the Insulin Pumps Market is poised for significant growth, driven by technological advancements such as the development of closed-loop systems (artificial pancreas technology), increasing awareness of diabetes management, and the rising prevalence of diabetes globally.

Will Rising Prevalence of Diabetes is Propelling the Insulin Pumps Market?

The rising prevalence of diabetes is significantly propelling the Insulin Pumps Market. As the global population continues to grow and age, the incidence of diabetes, particularly Type 2 Diabetes, is on the rise. According to the International Diabetes Federation (IDF), approximately 537 million adults worldwide were living with diabetes in 2021, a figure projected to reach 783 million by 2045. In the United States, the Centers for Disease Control and Prevention (CDC) reported that around 37.3 million people had diabetes in 2022, accounting for about 11.3% of the population. This increasing number of diabetes cases directly correlates with a heightened demand for effective management solutions, including insulin pumps.

The need for advanced diabetes management tools is further underscored by the growing recognition of the benefits that insulin pumps offer, such as improved glycemic control and greater flexibility in insulin delivery. As healthcare providers advocate for innovative treatment options to help patients manage their condition effectively, insulin pumps are becoming an integral part of diabetes care. The CDC also emphasizes that managing diabetes effectively can reduce complications, enhance the quality of life, and lower healthcare costs.

Will High Development Cost Hamper the Growth of the Insulin Pumps Market?

High development costs are indeed a significant factor that may hamper the growth of the Insulin Pumps Market. Developing advanced insulin pump technology requires substantial investments in research and development, regulatory compliance, and clinical trials to ensure safety and efficacy. These costs can deter smaller companies from entering the market and limit competition, potentially resulting in fewer innovative solutions and slower advancements in technology. Furthermore, the high price of insulin pumps often translates to elevated retail prices, which can restrict access for patients, particularly in regions with limited insurance coverage or high out-of-pocket expenses.

Additionally, the financial burden of high development costs can impact the pricing strategies of manufacturers. Companies may be compelled to pass on these costs to consumers, making insulin pumps less affordable and limiting their adoption among potential users. This can be particularly detrimental in the context of Type 2 Diabetes, where patients may be reluctant to invest in expensive devices without immediate health benefits.

Category-Wise Acumens

Will Consistent Insulin Delivery in Type 1 Diabetes Boost the Insulin Pumps Market?

Consistent insulin delivery in Type 1 Diabetes is expected to significantly boost the Insulin Pumps Market. Individuals with Type 1 Diabetes require precise and regular insulin administration to maintain optimal blood glucose levels and avoid complications associated with the disease. Insulin pumps provide a continuous delivery system, allowing users to adjust their insulin intake based on their activity levels, dietary intake, and blood sugar readings. This technology offers a more flexible and user-friendly approach compared to traditional insulin injections, leading to improved adherence to treatment regimens and better overall health outcomes for patients.

Furthermore, advancements in insulin pump technology, such as integration with continuous glucose monitoring systems and smart features that facilitate automated insulin delivery, are enhancing their appeal to Type 1 Diabetes patients.

The Type 2 Diabetes segment is the fastest growth, driven by rising obesity rates, lifestyle changes, and increasing awareness of diabetes management options.

Will Increasing Consumer Demand for Traditional Insulin Pumps Fuel the Insulin Pumps Market?

The increasing consumer demand for traditional insulin pumps is expected to significantly fuel the Insulin Pumps Market. Traditional insulin pumps are known for their reliability and advanced features, such as programmable insulin delivery rates and continuous glucose monitoring capabilities. As more patients seek effective diabetes management solutions, these devices are becoming increasingly popular among individuals requiring intensive insulin therapy. The integration of smart technology into traditional pumps also enhances their appeal, offering patients greater control over their diabetes management.

Moreover, the growing awareness of diabetes management among healthcare providers and patients alike is contributing to the rising demand for traditional insulin pumps. Educational initiatives and government programs promoting advanced diabetes care are further driving this trend.

The fastest-growing segment is the tubeless pumps, driven by their convenience, portability, and ease of use, which enhance patient adherence to diabetes management.

Country/Region-wise

Will Advanced Technological Infrastructure in North America Drive the Expansion of The Insulin Pumps Market?

Advanced technological infrastructure in North America is expected to drive the expansion of the Insulin Pumps Market. North America, particularly the United States, has a highly developed healthcare system, characterized by the rapid adoption of innovative medical technologies. Insulin pumps, which offer precise insulin delivery, benefit from this environment due to the availability of advanced manufacturing facilities and robust research and development in medical devices. The United States government has also promoted healthcare initiatives that support the use of advanced diabetes management technologies, contributing to the growing demand for insulin pumps.

Statistically, the prevalence of diabetes in North America further underscores the demand for insulin pumps. According to the U.S. Centers for Disease Control and Prevention (CDC), around 11.3% of the U.S. population, or approximately 37.3 million people, were living with diabetes as of 2022. This increasing diabetic population fuels the need for insulin pumps as an effective management tool. Additionally, government initiatives such as Medicare coverage for insulin pump users are likely to boost the market, with the Centers for Medicare & Medicaid Services (CMS) reporting a steady rise in reimbursements for diabetes-related technologies.

Will Increasing Adoption of Digital Technologies in Asia Pacific Propel the Insulin Pumps Market?

The increasing adoption of digital technologies in the Asia Pacific region is expected to significantly propel the Insulin Pumps Market. With growing cases of diabetes and the rise of digital healthcare, the demand for advanced insulin delivery systems has surged. Insulin pumps, which offer more precise control over blood glucose levels, have seen higher adoption due to improved digital interfaces and compatibility with smartphones. Governments across Asia Pacific are also pushing for better diabetes management through digital tools. For example, in India, the government has launched initiatives like the "Ayushman Bharat Digital Mission" to boost digital health infrastructure, increasing access to insulin pumps and other diabetes management devices.

Moreover, the region's governments are taking steps to combat the diabetes epidemic. According to the International Diabetes Federation (IDF), around 88 million adults in Southeast Asia were living with diabetes in 2021, and the numbers are expected to grow. In China, government health reports indicate that nearly 10% of the adult population suffers from diabetes, making it a focal market for insulin pump manufacturers. With such a high prevalence of diabetes and favorable government support, the insulin pump market in Asia Pacific is projected to grow robustly, driven by the rise in healthcare digitalization.

Competitive Landscape

The competitive landscape of the Insulin Pumps Market is characterized by a mix of established players and emerging startups, each focusing on innovative features such as real-time tracking, integration with IoT devices, and user-friendly interfaces. Companies are increasingly investing in research and development to enhance product offerings and improve customer service, creating a dynamic and rapidly evolving market environment.

Some of the prominent players operating in the Insulin Pumps Market include Medtronic plc, Hoffmann-La Roche Ltd, Insulet Corporation, Tandem Diabetes Care, Inc., SOOIL Development Co., Ltd., Becton, Dickinson and Company, Cellnovo Group, Ypsomed Holding AG, Medtrum, Inc., CanSino Biologics Inc.

Latest Developments

In August 2023 Medtronic announced the launch of its next-generation MiniMed 780G insulin pump system in Europe, featuring an advanced algorithm designed to automatically adjust insulin delivery every five minutes. This system also integrates with continuous glucose monitoring (CGM) and provides better glycemic control, particularly for patients with type 1 diabetes.

In July 2023 Roche launched its updated Accu-Chek Insight insulin pump system in select European countries. The new model offers enhanced precision in insulin dosing and integrates with digital health platforms, allowing patients and healthcare providers to monitor glucose levels and make real-time adjustments remotely.

In June 2023 Insulet received U.S. Food and Drug Administration (FDA) approval for its Omnipod 5 Automated Insulin Delivery System. This tubeless insulin pump integrates with Dexcom G6 CGM and allows users to control the system via a mobile app. The approval marked a significant step in expanding the options for people living with diabetes.